High Purity Semaglutide 5mg 10mg 15mg 20mg/Vial CAS 910463-68-2 Lyophilized Peptide Powder

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has attracted significant attention in the fields of metabolic research, glucose regulation, and body-weight management. Clinical studies have demonstrated that semaglutide may contribute to meaningful reductions in body weight while also supporting improvements in several metabolic parameters, including glycemic control and blood pressure.

Its long-acting pharmacological profile and once-weekly dosing formulation have made semaglutide an important advancement in GLP-1–based therapy and metabolic research.

Introduction

Semaglutide is a long-acting GLP-1 analog originally developed by Novo Nordisk. It was designed through structural modification of the native GLP-1 peptide to improve resistance to enzymatic degradation and prolong its biological activity.

Compared with earlier GLP-1 receptor agonists, semaglutide has an extended half-life, allowing sustained activity in the body. Its molecular design includes specific amino-acid substitutions and fatty-acid side-chain modification, which enhance stability and promote reversible binding to albumin.

Semaglutide has been extensively studied in clinical development programs for metabolic disorders, particularly type 2 diabetes and chronic weight management, and has become one of the most widely researched GLP-1 receptor agonists.

Mechanism and Characteristics

Semaglutide acts as a GLP-1 receptor agonist and mimics the activity of naturally occurring glucagon-like peptide-1. GLP-1 plays an important role in regulating glucose metabolism, insulin secretion, glucagon release, gastric emptying, and appetite signaling.

Key characteristics of semaglutide include:

• Long-acting GLP-1 receptor activity
• High structural stability
• Prolonged biological half-life
• Strong affinity for the GLP-1 receptor
• Potential effects on glucose regulation and energy intake
• Extensive application in metabolic and pharmaceutical research

Production and Structural Modification

Semaglutide is a modified peptide that can be prepared through controlled peptide synthesis and subsequent side-chain modification. During synthesis, the peptide backbone is assembled with specific amino-acid substitutions designed to improve molecular stability.

A fatty-acid-containing side chain is subsequently attached to a specific lysine residue through a linker structure. This modification enhances albumin binding and contributes to the prolonged pharmacokinetic profile of semaglutide.

Following synthesis, the peptide is typically subjected to purification and analytical characterization using techniques such as high-performance liquid chromatography and mass spectrometry to evaluate purity, identity, and structural consistency.

Research Applications

Semaglutide has been widely investigated in research related to:

GLP-1 receptor activity · Glucose metabolism · Insulin signaling · Appetite regulation · Energy metabolism · Body-weight management · Metabolic disease research

Tracking Number

Company Introduction